BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, December 26, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

June 23, 2016

View Archived Issues

Susceptible mouse model of ZIKV infection as a tool for testing novel vaccines and antivirals

Read More

Validation of C1M as a prognostic biomarker in rheumatoid arthritis structural progression

Read More

Incyte initiates phase I/II study of INCAGN-01876 for advanced or metastatic solid tumors

Read More

Cytonics' recombinant A2M variants attenuate cartilage degeneration in osteoarthritis models

Read More

FDA grants orphan drug designation to ANAVEX 2-73

Read More

Cellular Dynamics and National Eye Institute sign CRADA

Read More

Spring Bank Pharmaceuticals begins dosing in ACHIEVE phase II program

Read More

STAT3 inhibition shows positive preclinical results for the treatment of breast cancer

Read More

Asahi Kasei Pharma and Orion establish strategic collaboration in pain

Read More

NIH committee recommends approval of Dimension Therapeutics' phase I/II study of DTX-301

Read More

Epizyme closes deal with Genentech for tazemetostat + atezolizumab study

Read More

Yumanity announces collaboration with the New York Stem Cell Foundation Research Institute

Read More

Nymox Pharmaceutical announces long-term fexapotide prostate cancer study results

Read More

NCI Cancer Centers and Celgene enter landmark research consortium and collaborations

Read More

Celgene's CC-115 shows signs of activity in phase I cancer trial

Read More

ArQule initiates phase I study of ARQ-751 in patients with advanced solid tumors

Read More

Bionomics receives funds as part of licensing agreement for PRMT5 inhibitors

Read More

FDA grants orphan drug designation to napabucasin for the treatment of gastric cancer

Read More

Janssen R&D reports antiviral compounds

Read More

Merck & Co. discloses HIV integrase inhibitors

Read More

Bayer Schering Pharma patents HSKM-B inhibitors

Read More

Aquinnah Pharmaceuticals patent describes TDP-43 inhibitors

Read More

Rapid responses seen with TNT-009 in patients with cold agglutinin disease

Read More

ASLAN Pharmaceuticals' varlitinib receives FDA orphan drug designation

Read More

Kailos Genetics and HCI collaborate to develop ctDNA test to monitor breast cancer recurrence

Read More

Allogeneic stem cell treatment with SB-623 shows promise in stroke patients

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 24, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Acute myeloid leukemia illustration

    Apollo’s APL-4098 shows potent antileukemic effects

    BioWorld Science
    Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing